Clonidine Hydrochloride
Composition
Clonipres ER 0.1 Tablet: Each Extended release tablet contains Clonidine
Hydrochloride USP 0.1 mg.
Indications
Clonidine hydrochloride extended release tablet is indicated for
the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy.
Dosage and Administration
Attention deficit hyperactivity disorder : Clonidine ER
0.1 mg/day for 8 weeks
Vancomycin
Composition
Vanogut 125 Capsule: Each capsule contains Vancomycin Hydrochloride
USP equivalent to Vancomycin 125 mg.
Vanogut 250 Capsule: Each capsule contains Vancomycin Hydrochloride
USP equivalent to Vancomycin 250 mg.
Indications
Vancomycin is indicated for the treatment of C. difficile associated
diarrhoea & enterocolitis caused by Staphylococcus aureus (including
methicillin-resistant strains).
Dosage and Administration
C. difficile associated diarrhoea: The recommended dosage is 125 mg
administered 4 times daily for 10 days.
Staphylococcal enterocolitis: Total daily dose is 500 mg to 2 g administered
in 3 or 4 divided doses for 7 to 10 days.
For Paediatric Patients, the daily dosage is 40 mg/kg in 3 or 4 divided
doses for 7 to 10 days. The total daily dose should not exceed 2 g or as
directed by the physician.
Ceftriaxone
Composition
TopcefTM 500 mg IM Injection: Each vial contains dry substance
equivalent to 500 mg Ceftriaxone (as sterile Ceftriaxone Sodium BP)
with 2 ml Lidocaine Hydrochloride BP 1% Injection for IM injection.
TopcefTM 1 g IV Injection: Each vial contains dry substance equivalent
to 1 g Ceftriaxone (as sterile Ceftriaxone Sodium BP) with 10 ml Water
for Injection BP for IV injection.
TopcefTM 2 g IV Injection: Each vial contains dry substance equivalent
to 2 g Ceftriaxone (as sterile Ceftriaxone Sodium BP) accompanied by
2 ampoules each contains 10 ml water for injection.
Indication
TopcefTM is indicated in sepsis, meningitis, neurosyphillis, abdominal
infections (peritonitis, infections of the biliary and gastrointestinal
tracts), infections of the bones, joints, soft tissue, skin and of wounds,
renal and urinary tract infections, respiratory tract infections, ear, nose
and throat infections, genital infections, including gonorrhoea,
perioperative prophylaxis of infections
Dosage and Administration
Adults and children over 12 years: The usual dose is 1-2 g of TopcefTM
once daily (every 24 h). In severe cases, the dose may be raised to 4 g
once daily. Neonates, infants and children up to 12 years: Neonates
(up to 14 days): A daily dose of 20-50 mg/kg body weight, not to
exceed 50 mg/kg. Infants and children (15 days to 12 years): A daily
dose of 20-80 mg/kg. For children with body weights of 50 kg or more,
the usual adult dose should be used. Elderly patients: The dosage
recommended for adults require no modification in case of geriatric
patients. Duration of therapy: The usual duration of therapy is 4 to 14
days; in complicated infections, longer therapy may be required. When
treating infections caused by Streptococcus pyogenes, therapy should
be continued for at least 10 days. Meningitis: In bacterial meningitis in
infants and children, treatment begins with dose of 100 mg/kg (not to
exceed 4 g) once daily. Gonorrhoea: a single IM dose of 250 mg
TopcefTM is recommended. Perioperative prophylaxis: a single dose of
1-2 g depending on the risk of infection of 30-90 minutes prior to
surgery. In colorectal surgery, administration of TopcefTM with or without
a 5-nitroimidazole, e.g. Ornidazole, has been proven effective.
Impaired renal and hepatic function: In patients with impaired renal
function, there is no need to reduce the dosage of TopcefTM provided
hepatic function is intact. In patients with liver damage, there is no
need for the dosage to be reduced provided renal function is intact Or
as directed by the physician.
Meropenem
Composition
InpenTM 500 mg IV injection: Each vial contains Meropenem USP 500 mg.
InpenTM 1 g IV injection: Each vial contains Meropenem USP 1 g.
Indications
InpenTM is indicated for treatment, in adults and children, of the following infections caused by single or multiple susceptible bacteria and as empiric therapy prior to the
identification of the causative organisms:
Lower Respiratory Tract Infections, Urinary Tract Infections, including complicated infections Intra-abdominal Infections, Gynaecological infections, including
postpartum infections, Skin and Skin Structure Infections, Meningitis, Septicaemia, Empiric treatment, including initial monotherapy, for presumed bacterial
infections in host-compromised, neutropenic patient.
Because of its broad spectrum or bactericidal activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria. InpenTM is effective for the treatment of
polymicrobial infections.
Dosage and Administration
ADULTS:
Usual dose: 500 mg to 1 g by intravenous administration every 8 hours depending on type end severity of Infection.
Exceptions: 1. Febrile episodes to neutropenic patients - the dose should be I g every 8 hours. 2. Meningitis- the dose should be 2 g every 8 hours.
As with other antibiotic, caution may be required in using Meropenem as monotherapy in critically iII patients with known or suspected Pseudomonas aeruginosa lower
respiratory tract erections. Regular sensitivity testing is recommended when treating Pseudomonas aeruginosa infections.
InpenTM should be given as an intravenous bolus injection over approximately 5 minutes or by intravenous infusion over approximately 15 to 30 minutes (see Method of
Administration).
ELDERLY
No dosage adjustment is required for the elderly with normal renal function or creatinine clearance values above 50 ml/min.
CHILDREN
For infants and children over 3 months and up to 12 years of age the recommended intravenous dose is 10 to 40 mg/kg every 8 hours depending on type and severity of
infection, the known or suspected susceptibility of the pathogen(s) and the condition of the patient. In children over 50 kg weight, adult dosage should be used
Ciprofloxacin
Composition
Floxacin 500 mg Tablet : Each tablet contains Ciprofloxacin
Hydrochloride USP equivalent to 500 mg Ciprofloxacin.
Indications
lInfectious diarrhoea lUrinary tract infection lTyphoid fever lLower
respiratory tract infection lAcute sinusitis lBone and joint infection
lChronic bacterial prostitis l Pyelonephritis l Gonococcal infection l
Inhalational anthrax.
Flibanserin
Composition
Fevigra Tablet: Each film coated tablet contains Flibanserin INN 100 mg.
Indications
Flibanserin is indicated for the treatment of premenopausal women with
acquired or generalized hypoactive sexual desire disorder (HSDD).
Dosage & Administration
The recommended dosage of Flibanserin is 100 mg administered once per
day at bedtime. Or as directed by the physician
Ertugliflozin
Composition
Ertuglif 5: Each film coated tablet contains Ertugliflozin L-Pyroglutamic Acid INN equivalent to Ertugliflozin 5 mg.
Pharmacology
SGLT2 is the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. Ertugliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, ertugliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose and thereby increases urinary glucose excretion.
Indication
Ertugliflozin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults
with type 2 diabetes mellitus.
Dosage & Administration
The recommended starting dose of Ertugliflozin is 5 mg once daily taken in the morning with or
without food. In patients tolerating Ertugliflozin 5 mg once daily, the dose may be increased to a
maximum recommended dose of 15 mg once daily if additional glycaemic control is needed or as directed by the physician.
Contraindications
Severe renal impairment, end-stage renal disease (ESRD) or dialysis. History of a serious
hypersensitivity reaction to Ertugliflozin.
Use in Pregnancy & Lactation
Pregnancy: Ertugliflozin is not recommended during the second and third trimesters of
pregnancy. The limited available data with Ertugliflozin in pregnant women are not sufficient to determine a drug-associated risk of adverse developmental outcomes. There are risks to the
mother and fetus associated with poorly controlled diabetes in pregnancy.
Lactation: Ertugliflozin is not recommended while breastfeeding.
Use in Children & Adolescents
Pediatric Use: Safety and effectiveness of Ertugliflozin in pediatric patients under 18 years of age have not been established.
Geriatric Use: No dosage adjustment of Ertugliflozin is recommended based on age.
Drug Interactions
Concomitant Use with Insulin and Insulin Secretagogues Ertugliflozin may increase the risk of hypoglycemia when used in combination with insulin and/or an insulin secretagogue. Therefore, a lower dose of insulin or insulin secretagogue may be required to minimize the risk of hypoglycemia when used in combination with Ertugliflozin.
Overdosage
In the event of an overdose with Ertugliflozin contact the Poison Control Center. Employ the usual supportive measures as dictated by the patient’s clinical status. Removal of ertugliflozin by hemodialysis has not been studied.
Storage
Store below 30°C, away from light and in a dry place. Keep all medicines out of the reach of
children.
Baclofen
Composition:
MyobacTM 5 Tablet : Each tablet contains Baclofen USP 5 mg.
MyobacTM 10 Tablet : Each tablet contains Baclofen USP 10 mg.
Pharmacology:
MyobacTM (Baclofen) is an effective muscle relaxant and
antispastic agent with a spinal site of action. It exerts its action by
inhibiting both monosynaptic and polysynaptic transmission in the
spinal cord by stimulating GABAB receptors.
Indications:
MyobacTM (Baclofen) is indicated for the alleviation of spasticity
resulting from multiple sclerosis particularly for the relief of flexor
spasm and concomitant pain, clonus and muscular rigidity, spinal
cord diseases, muscle spasm of cerebral origin especially infantile
cerebral palsy, stroke or neoplastic or degenerative brain diseases.
It may be of some value in patients with trigeminal neuralgia,
tardive dyskinesia, cluster headache & tension type headache.
Dosage & Administration:
Muscle relaxant & spasticity
For adults: Start at a low dosage and increase gradually until the
optimum effect is achieved (usually 40-80mg daily). Initially 5 mg
three times daily for 3 days; then 10 mg three times daily for 3
days, 15 mg three times daily for 3 days and 20 mg three times
daily for 3 days. Additional increases in dose may be required but
should not exceed 20 mg four times daily.
For Children: (treatment of spasticity): 0.75-2 mg/kg daily (over 10
years, max. 2.5 mg/kg daily) or 2.5 mg 4 times daily increased
gradually according to age to maintenance: 1-2 years 10-20 mg
daily, 2-6 years 20-30 mg daily, 6-10 years 30-60 mg daily.
Or as directed by the physician.
Contraindications:
MyobacTM (Baclofen) is contraindicated in patients who are
hypersensitive to any component of this preparation.
Warning and precaution:
Hallucinations and seizures may occur on abrupt withdrawal of
MyobacTM (Baclofen). Therefore, except for serious adverse
reactions, the dose should be reduced slowly when the drug is
discontinued.
Side effects:
Common side effects: Agitation, anxiety, ataxia, cardiovascular
depression, confusion, depression, dizziness, drowsiness, dry
mouth, euphoria, gastrointestinal disturbances, hallucinations,
headache, hypotension, insomnia and myalgia.
Rare side effects: Abdominal pain, changes in hepatic function, c,
paraesthesia and taste disturbances.
Nabumeton
Composition : Nabuton 500 Tablet: Each film coated tablet contains Nabumetone BP 500 mg.
Nabuton 750 Tablet: Each film coated tablet contains Nabumetone BP 750 mg.
Pharmacology: Nabumetone is a non-steroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory,
analgesic and antipyretic properties in pharmacological studies. As with other non-steroidal
anti-inflammatory agents, it's mode of action is not known; however, the ability to inhibit
prostaglandin synthesis may be involved in the anti-inflammatory effect. The active ingredient is a
prodrug, which undergoes hepatic biotransformation to the active component,
6-methoxy-2-naphthylacetic acid (6MNA), that is a potent inhibitor of prostaglandin synthesis.
Indication:
Nabuton tablet is indicated for acute and chronic treatment of signs and symptoms of osteoarthritis
and rheumatoid arthritis.
Dose & Administration :Osteoarthritis and Rheumatoid arthritis: The recommended starting dose is 1000 mg taken as a
single dose with or without food. Some patients may obtain more symptomatic relief from 1500 mg to
2000 mg per day. Nabumetone can be given in either a single or twice-daily dose. Dosage greater
than 2000 mg per day have not been studied. The lowest effective dose should be used for chronic
treatment. Caution should be used in prescribing Nabumetone to patient with moderate or severe
renal insufficiency. The maximum starting dose of Nabumetone in patients with moderate or severe
renal insufficiency should not exceed 750 mg or 500 mg, respectively once daily. Following careful
monitoring of renal function in patients with moderate or severe renal insufficiency, daily doses may
be increased to a maximum of 1500 mg and 1000 mg, respectively or as directed by the
physicians.
Contraindication : Hypersensitivity NSAID induced asthma, urticaria or other allergic type reactions.
Luliconazole
Composition:
Lulider Cream: Each gram cream contains Luliconazole INN 10 mg.
Pharmacology:
Exact mechanism of action against dermatophytes is unknown.
Luliconazole appears to inhibit ergosterol synthesis by inhibiting
the enzyme lanosterol demethylase. Inhibition of this enzyme’s
activity by azoles results in decreased amount of ergosterol, a
constituent of fungal cell membranes and a corresponding
accumulation of lanosterol.
Indication:
Lulider Cream is indicated for the topical treatment of interdigital
Tinea pedis, Tinea cruris and Tinea corporis, in patients 2 years of
age and older.
Dosage & Administration:
Tinea pedis: A thin layer of cream should be applied to the
affected area and approximately 1 inch of the immediate
surrounding area(s) once daily for two weeks.
Tinea cruris and Tinea corporis: A thin layer of cream, should be
applied to the affected area and approximately 1 inch of the
immediate surrounding area(s) once daily for one week or as
directed by the physician.
Naviscon Sodium Alginate BP, Sodium Bicarbonate BP & Calcium Carbonate USP
Composition
Naviscon Suspension: Each 10 ml suspension contains Sodium Alginate BP 500 mg, Sodium Bicarbonate BP 267 mg & Calcium Carbonate USP 160 mg. Naviscon Chewable Tablet: Each chewable tablet contains Sodium Alginate BP 250 mg, Sodium Bicarbonate BP 133.5 mg & Calcium Carbonate USP 80 mg.
Pharmacology
The mode of action of the product is non-systemic and does not depend on absorption into the systemic circulation. On ingestion, the product reacts rapidly with gastric acid to form a raft of Alginic acid gel having a near-neutral pH and which floats on the stomach contents quickly and effectively impeding gastro-esophageal reflux, for up to 4 hours. In severe cases, the raft itself may be refluxed into the esophagus in preference to the stomach contents and exert a demulcent effect. Indications Naviscon is indicated for the treatment of heartburn, heartburn of pregnancy, dyspepsia associated with gastric reflux, hiatus hernia, reflux esophagitis, regurgitation and all cases of epigastric and retrosternal distress where the underlying cause is gastric reflux.
Dosage & Administration
Naviscon Suspension: Adult and children over 12 years: 10-20 ml after meals and at bedtime, up to four times a day. Children 6 to 12 years: 5-10 ml after meals and at bedtime, up to four times a day. Children under 6 years: Not recommended. shake well before each use. Chewable Tablet: Adult and children over 12 years: 2-4 tablets after meals and at bedtime, up to four times a day. Children under 12 years: Should be given only on doctor advice. Elderly: No dosage modification is required for this age group. Hepatic Impairment: No dose modification necessary.
Contraindication
This product is contraindicated in patients with known or suspected hypersensitivity to the active ingredients or to any of the excipients.
Warnings & Precautions
If symptoms do not improve after 7 days, the clinical situation should be reviewed. This should be taken into account when a highly restricted salt diet is recommended e.g. in some cases of congestive cardiac failure and renal impairment. Care needs to be taken in treating patients with hypercalcaemia, nephrocalcinosis and recurrent calcium containing renal calculi.
Side Effects
In addition to the desired effect of the drug, some side effects may appear such as constipation, flatulence, stomach cramp or belching. If too big dose has been taken, there might appear a sensation of swelling in stomach. In these cases consult a physician.
Doxofylline
Composition
Filodox SR Tablet: Each sustained release tablet contains Doxofylline INN 400
mg.
Filodox 400 Tablet: Each film coated tablet contains Doxofylline INN 400 mg.
Filodox 200 Tablet: Each film coated tablet contains Doxofylline INN 200 mg.
Filodox 100 ml Syrup: Each 5 ml syrup contains Doxofylline INN 100 mg.
Pharmacology
Filodox (Doxofylline) is a novel bronchodilator. It structurally differs from
Theophylline due to presence of a dioxolane group in position 7. Doxofylline
selectively inhibits phosphodiesterase-4 thereby relaxes bronchial smooth
muscle. However, differently from Theophylline, Doxophylline appears to have
decreased affinities toward adenosine A1 and A2 receptors, which may account
for the better safety profile of the drug. Doxofylline is reported to inhibit platelet
activating factor (PAF) and leukotriene production.
Indications
Filodox (Doxofylline) is used to treat COPD, asthma and bronchospasm.
Dosage and Administration
Elderly: 200 mg Tablet two or three times daily.
Adults: 400 mg Tablet two or three times daily or as prescribed by physician.
Children 6 years over: 6 mg/ kg body weight two or three times daily.
If daily required dose of Doxofylline is 400 mg, then Filodox SR Tablet to be
taken once daily or as directed by the physician.
Itraconazole
Composition:
Itracon 100 Capsule: Each capsule contains Itraconazole pellets equivalent to Itraconazole
USP 100 mg.
Itracon 200 Tablet: Each film coated tablet contains Itraconazole USP 200 mg.
Itracon Oral Solution: Each 5 ml oral solution contains Itraconazole USP 50 mg.
Pharmacology:
Itracon is a preparation of Itraconazole, an orally active triazole antifungal agent, having broad
spectrum activity and favourable pharmacokinetic profile. Itraconazole inhibits cytochrome
P450 dependent enzymes resulting in impairment of the biosynthesis of Ergosterol, a major
component of the cell membrane of yeast and fungal cells.
Indications:
Itracon Capsule & Tablet: Tinea corporis, Tinea cruris, Tinea pedis, Tinea manuum,
Vulvovaginal candidiasis, Fungal keratitis, Pityriasis versicolor, Oropharyngeal candidiasis,
Onychomycosis, Histoplasmosis, Systemic Infections: Aspergillosis, Candidiasis and
Cryptococcal infection when other drugs are ineffective. Antifungal prophylaxis: To prevent
systemic fungal infection in severely neutropenic patients.
Itracon Oral Solution: It is indicated for the treatment of Oropharyngeal Candidiasis &
Esophageal Candidiasis.
Dosage & Administration:
Itracon Tablet & Capsule:
Tinea corporis, Tinea cruris: 100 mg daily for 2 weeks.
Tinea pedis, Tinea manuum: 100 mg daily for 4 weeks.
Vulvovaginal candidiasis: 200 mg twice daily for 1 day.
Fungal keratitis: 200 mg daily for 3 weeks.
Pityriasis versicolor: 200 mg daily for 1 week.
Oropharyngeal candidiasis: 100 mg daily (200 mg for immuno-compromised patients) for 15
days.
Onychomycosis: 200 mg daily for 3 months; or 200 mg twice daily for 7 days (course),
subsequent courses to be repeated after 21 days interval; fingernails 2 courses and toenails 3
courses.
Histoplasmosis: 200 mg 1-2 times daily.
Systemic Infections: 200 mg once daily (Aspergillosis, Candidiasis and Cryptococcus infection
when other drugs are ineffective), increased in invasive or in cryptococcal meningitis to 200 mg
twice daily.
Antifungal prophylaxis: To prevent systemic fungal infection in severely neutropenic patients
100 mg daily.
Itracon Oral Solution: This solution should be vigorously swished in the mouth (10 ml at a time)
for several seconds and swallowed. The recommended dosage of Itracon oral solution for
Oropharyngeal Candidiasis is 200 mg (20 ml) daily for 1 to 2 weeks. The recommended
dosage of Itracon oral solution for Esophageal Candidiasis is 100 mg (10 ml) daily for a
minimum treatment of 3 weeks. Child Dose: 5 mg / kg once daily for 14 days. For oral use only
(for 1 month to 11 years of age) or as directed by the physician.
Vonoprazan
Vontac 10: Each film coated tablet contains Vonoprazan fumarate INN equivalent
to Vonoprazan 10 mg.
Vontac 20: Each film coated tablet contains Vonoprazan fumarate INN equivalent
to Vonoprazan 20 mg.
Dosage & Administration
• Gastric ulcer & duodenal ulcer: The usual adult dosage is 20 mg once daily, 8 week
treatment for gastric ulcer and a 6-week treatment for duodenal ulcer.
• Reflux esophagitis: The usual adult dose is 20 mg once daily for a total of 4 weeks of
treatment. If that dosing proves insufficient, the administration should be extended, but
for no longer than 8 weeks of treatment.
• For the maintenance therapy of reflux esophagitis showing recurrence. The dose is 10
mg once daily. When the efficacy is inadequate, the dosage may be increased up to 20
mg once daily.
• Prevention of recurrence of gastric or duodenal ulcer during low-dose aspirin
administration: The usual adult dose is 10 mg once daily.
• Prevention of recurrence of gastric or duodenal ulcer during non-steroidal
anti-inflammatory drug (NSAID) administration: The usual adult dose is 10 mg once
daily.
• Adjunct to Helicobacter pylori eradication: For adults, the following three-drug regimen
should be administered orally at the same time twice daily for seven days: 20 mg dose
of Vonoprazan, 750 mg dose of amoxicillin hydrate and 200 mg dose of clarithromycin.
• If Helicobacter pylori eradication with a three-drug regimen comprising a proton pump
inhibitor, amoxicillin hydrate and clarithromycin has been unsuccessful, as an alternative
treatment, adults should be administered the following three drugs twice daily for seven
days: 20 mg of Vonoprazan, 750 mg of amoxicillin hydrate and 250 mg of Metronidazole
or as directed by the physicians.
Roflumilast INN 0.3%
Composition:
Lumilast Cream: Each gram cream contains Roflumilast INN 3 mg.
Indication:
Lumilast cream is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age and older.
Dosage & Administration:
Lumilast cream should be applied on affected areas once daily and rubbed in completely. Hands should be washed after application, unless the cream is for treatment of the hands. Lumilast cream is for topical use only and not for ophthalmic, oral, or intravaginal use or as directed by the physician.
Dextromethorphan + Levomenthol + Diphenhydram
Composition:
Pires™-D Syrup: Each 5 ml syrup contains Dextromethorphan Hydrobromide BP 6.5 mg, Levomenthol BP 2 mg and Diphenhydramine Hydrochloride BP 14 mg.
Indication:
Pires™-D Syrup is indicated as an antitussive, for the relief of persistent, dry, irritating cough, and aiding restful sleep.
Dose & Administration:
Adults and children over 12 years: 2 teaspoonful syrup 4 times a day or as directed by the physicians. Do not take more than 8 teaspoonful syrup in 24 hours.
Clascoterone
Composition:
Clascon cream: Each gram cream contains Clascoterone INN 10 mg.
Indication:
Clascon cream is indicated for the topical treatment of acne vulgaris in patients of 12 years of age and older.
Dose & Administration:
Clean the affected area gently then apply a thin uniform layer of Clascon cream twice per day in the morning and evening to the affected area. Avoid accidental transfer of Clascon cream into eyes, mouth or other mucous membranes. If contact with mucous membranes occurs, this should be rinsed thoroughly with water or as directed by the physician.
Guaifenesin + Levomenthol + Diphenhydram
Composition:
Pires™-M Syrup: Each 5 ml syrup contains Guaifenesin BP 100 mg,Levomenthol BP 1.1 mg and Diphenhydramine Hydrochloride BP 14 mg.
Indication:
Pires™-M Syrup is indicated for the relief of cough, associated congestive symptoms and aiding restful sleep.
Dose & Administration:
Adults and children over 12 years: 2 teaspoonful syrup 4 times a day or as directed by the physicians. Do not take more than 8 teaspoonful syrup in 24 hours.
Fluticasone Propionate
Composition:
Flutispray™ Nasal Spray: Each spray contains
Fluticasone Propionate BP 50 meg.
Indication:
Flutispray™ is indicated for the management of the nasal symptoms of seasonal & perennial allergic & non-allergic rhinitis in adults and paediatric patient 4 years of age and older.
Dose & Administration:
Adults 02 (two) sprays in each nostril once daily, preferably in the morning.
In some cases, 02 (two) sprays in each nostril twice daily may be required or as directed by the physician.
Total daily doses of 200 meg (04 sprays) should not generally be exceeded.
Children (4 to 11 years of age) 01 (one) spray in each nostril once daily. In some cases, 01 (one) spray in each nostril twice daily may be required or as directed by the physician.
Total daily doses of 100 meg (2 sprays) should not generally be exceeded or as directed by the physicians
Etoricoxib
COMPOSITION
Torcox™ 60 Tablet : Each film coated tablet contains Etoricoxib INN 60 mg.
Torcox™ 90 Tablet : Each film coated tablet contains Etoricoxib INN 90 mg.
Torcox™ 120 Tablet : Each film coated tablet contains Etoricoxib INN 120 mg.
INDICATION
Torcox™ (Etoricoxib) is indicated for relief of pain and inflammation in -• Osteoarthritis
• Rheumatoid arthritis
• Ankylosing spondylitis
• Other chronic musculoskeletal disorders
• Acute gout
• Primary dysmenorrhoea &
• Dental pain
DOSE AND ADMINISTRATION
Pain and inflammation in Osteoarthritis:
• Child 16-17 years: 30 mg once daily, increased if necessary to 60 mg once daily
• Adult: 30 mg once daily, increased if necessary to 60 mg once daily. Pain and inflammation in rheumatoid arthritis & Ankylosing spondylitis:
• Child 16-17 years: 60 mg once daily, increased if necessary to 90 mg once daily.
Adult: 60 mg once daily, increased if necessary to 90 mg once daily.
Acute gout:
• Child 16-17 years: 120 mg once daily for maximum 8 days
• Adult: 120 mg once daily for maximum 8 days
Dental pain:
• 90-120 mg once daily for maximum 8 days.
Primary dysmenorrhoea
• 120 mg once daily for maximum 8 days
or as directed by the physician
Empagliflozin + Metformin
Composition
Glifomet Tablet: Each film coated tablet contains Empagliflozin INN 5 mg and Metformin Hydrochloride BP 500 mg.
Indication
Glifomet is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type
2 diabetes mellitus when treatment with both Empagliflozin and Metformin Hydrochloride is
inappropriate. Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2
diabetes mellitus and established cardiovascular disease
Dose & Administration
• The starting dose of Glifomet should be based on the patient's current regimen.
• Take twice daily with meals, with gradual dose escalation to reduce the gastrointestinal side effects due to Metformin Hydrochloride.
• The maximum recommended dose is 12.5 mg empagliflozin /1 000 mg metformin hydrochloride twice daily.
• Assess renal function before initiating Glifomet. Do not initiate or continue Glifomet if creatinine levels are greater than or equal to 1.5 mg /dL for males or 1.4 mg /dL for females or if eGFR is below 45 mL /min II.73 m2 or as directed by the physician.
Ozenoxacin
Composition:
Zenocin Cream: Each gram cream contains Ozenoxacin INN 10 mg.
Indication:
Zenocin Cream is indicated for the topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and paediatric patients 2 months of age and older.
Dose & Administration:
Apply a thin layer of Zenocin cream topically to the affected area twice daily for five days or as directed by the physicians.
Domperidon
Composition:
Vomitop Tablet: Each film coated tablet contains Domperidone maleate BP equivalent to 10 mg Domperidone.
Indication:
Prevention & symptomatic relief of acute nausea and vomiting of adults (from any cause specially due to cytotoxic therapy & radiotherapy).Nausea & vomiting associated with L-dopa and bromocriptine treatment for parkinsonian patients. Nausea & vomiting due to migraine, head injury, pancreatitis,gastritis, hepatitis, post-gastrectomy syndrome, haemodialysis and dysmenorrhoea. Non ulcer dyspepsia, oesophageal reflux, reflux oesophagitis & gastritis. Speeding of barium transit in 'follow through' radiological studies.
Dose & Administration:
The recommended dosage for Adult & Elderly patients: 10-20 mg every 4-8 hours. Domperidone should be taken 15-30 minutes before meal. Or as directed by the physician
Omeprazole
Composition
Ometac™ 20: Each capsule contains Omeprazole BP 20 mg.
Indications:
It is used for the treatment of oesophageal reflux disease, duodenal and benign gastric ulcer including those complicating NSAID therapy, Zollinger Ellison syndrome.
Dose & Administration:
Reflux Oesophagitis : The usual dose is 20 mg once daily for 4 weeks. For those patients not fully healed after the initial course ,a further 4-8 weeks treatment may require. Or as directed by the physician.
Amorolfine
Composition:
Curafin Cream: Each gram cream contains Amorolfine Hydrochloride BP equivalent to Amorolfine 2.5 mg.
Indication:
Curafin Cream is indicated for the treatment of Tinea pedis (athlete's foot), Tinea cruris, Tinea inguinalis,Tinea corporis,Tinea manuum & Pityriasis versicolor.
Dose & Administration:
To be applied to affected skin areas once daily following cleansing (in the evening).The treatment should be continued without interruption until clinical cure, and for 3 -5 days
thereafter. The required duration of treatment depends on the species of fungi and on the localization of the infection. In general, treatment should be continued for at least two
to three weeks. With foot mycoses, up to six weeks of therapy may be necessary or as directed by the physicians
Metformine
Composition:
NVmet™ 500 Tablet: Each film coated tablet contains Metformin Hydrochloride BP 500 mg.
NVmet™ 850 Tablet: Each film coated tablet contains Metformin Hydrochloride BP 850 mg.
NVmet™ 500 SR Tablet: Each sustained release tablet contains Metformin Hydrochloride BP 500 mg.
Indication:
NVmet™, as monotherapy, is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. NVmet™ is also indicated for use in combination with other agents, that do not result in adequate glycemic control.
Dose and administration:
Diabetes mellitus: Adult and child over 10 years initially 500 mg with breakfast for at least 1 week, then 500 mg with breakfast and evening meal for at least 1
week, then 500 mg with breakfast, lunch and evening meal; usual max. 2 g daily in divided doses.
Polycystic ovary syndrome: initially 500 mg with breakfast for 1 week, then 500 mg with breakfast and evening meal for 1 week, then 1.5-1.7 g daily in 2-3 divided doses or as directed by the physician.
Gliclazide
Composition:
Glix™ 80 Tablet: Each Tablet contains Gliclazide BP 80 mg.
Glix™ 60 MR Tablet: Each modified release tablet contains Gliclazide BP 60 mg.
Indication:
Indicated for the treatment of Type-2 Diabetes.
Dose & Administration:
Glix™ 80 Tablet: Initially 40-80 mg daily, adjusted according to response, increased if necessary up to 160 mg once daily. Dose to be taken with breakfast, dosage higher than 160 mg to be given in divided doses; maximum 320 mg per day.
Glix™ MR Tablet: Initially 30 mg daily, dose to be taken with breakfast, adjustdose according to response every 4 weeks (after 2 weeks if no decrease in blood glucose); maximum 120 mg per day. Or as directed by the physician.
Linagliptin + Metformin
Composition:
Diplin™ M 500 Tablet: Each film coated tablet contains Linagliptin INN 2.5 mg & Metformin Hydrochloride BP 500 mg.
Indications:
Diplin™ M 500 is a dipeptidyl peptidase-4 (DPP-4) inhibitor and biguanide combination product indicated as
an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when
treatment with both Linagliptin and Metformin is appropriate.
Dose & Administration:
The maximum recommended dose is Linagliptin 2.5 mg/Metformin Hydrochloride 1000 mg twice daily Or as directed by the physician.
Linagliptin
Composition
Diplin 5 Tablet: Each film coated tablet contains Linagliptin INN 5 mg.
Pharmacology
Diplin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which is believed to exert its actions in patients with type 2 diabetes by slowing the inactivation of incretin hormones. Incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are released by the intestine throughout the day and levels are increased in response to a meal. These hormones are rapidly inactivated by the enzyme, DPP-4. The incretins are part of an endogenous system involved in the physiologic regulation of glucose homeostasis. When blood glucose concentrations are normal or elevated, GLP-1 and GIP increase insulin synthesis and release from
pancreatic beta cells by intracellular signaling pathways involving cyclic AMP. GLP-1 also lowers glucagon secretion from pancreatic alpha cells, leading to reduce hepatic glucose production. By increasing and prolonging active incretin levels, Diplin increases insulin release and decreases glucagon levels in the circulation in a glucose-dependent manner.
Indication
Diplin is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.
Dose & Administration
The recommended dose of Diplin is 5 mg once daily. No dosage adjustment is required for hepatic or kidney impaired patients or as directed by the physician.
Nortripline
Composition:
Nortin™ 10 Capsule: Each capsule contains Nortriptyline Hydrochloride BP equivalent to 10 mg Nortriptyline.
Nortin™ 25 Capsule: Each capsule contains Nortriptyline Hydrochloride BP equivalent to 25 mg Nortriptyline.
Indication:
Depressive illness, Panic disorder & Neuropathic pain.
Dosage & administration:
Depression, low dose initially increased as necessary to 75-100 mg daily in divided doses or as a single dose (max. 150 mg daily);
Adolescent and Elderly patient : 30- 50 mg daily in divided doses. Neuropathic pain, initially 10 mg daily at night, gradually increased if
necessary to 75 mg daily; higher doses under specialist supervision. Or as directed by the physician
Flupentixol+ Melitracen
Composition:
Meltix™ Tablet: Each film coated tablet contains Flupentixol
Dihydrochloride BP equivalent to 0.5 mg Flupentixol and Melitracen Hydrochloride INN equivalent to 10 mg Melitracen.
Indications:
It is indicated in various types of anxiety, depression and apathy.
These include-) Psychogenic depression
a. Depressive neurosis
b. Masked depression
c. Psychosomatic affections accompanied by anxiety and apathy.
d. Menopausal depressions
e. Dysphoria and depression in alcoholics and drug-addicts.
Dosage & Administration:
Adults : Usually 2 tablets daily at morning and noon. In severe cases the
morning dose may be increased to 2 tablets.
Elderly patients : 1 tablet in the morning.
Maintenance dose : Usually 1 tablet in the morning. In cases of insomnia or severe restlessness additional treatment with a sedative in acute phase is recommended. Or as directed by the physician.
Clonazepam
Composition
Conpan ODT 0.5 : Each orally disintegrating tablet contains Clonazepam USP 0.5 mg.
Conpan ODT 1 : Each orally disintegrating tablet contains Clonazepam USP 1 mg.
Conpan ODT 2 : Each orally disintegrating tablet contains Clonazepam USP 2 mg.
Indications
Clonazepam is indicated in all forms of epilepsy, status epilepticus, infantile spasms,
myoclonic seizures, akinetic and atonic seizures, partial seizures, bipolar affective
disorder, panic attacks etc.
Dosage & Administration
The standard dose of clonazepam must be individually adjusted according to the patient's
clinical response and tolerance of the drug. As a general rule, Clonazepam is started with
low single dose in a new patient. Adults: 1mg (elderly, 0.5 mg), initially at night for 4
nights, increased according to response over 2-4 weeks to usual maintenance dose of 4-8
mg which is usually given at night as a single dose or may be given in 3-4 divided doses if
necessary. Children: Up to 1 year, initially 0.25 mg, increased as above to usual
maintenance dose of 0.5-1 mg, 1-5 years initially 0.25 mg, increased as above to 1-3 mg,
5-12 years, initially 0.5 mg, increased as above to 3-6 mg.
Direction for administration of Conpan Orally Disintegrating Tablet:
This tablet must be handled with dry hand. The tablet to be placed on tongue and let it be
dissolved. It should not be chewed, broken, or crushed. Like other conventional oral
tablets, it also can be swallowed with a glass of water or as directed by the physician.
Clonidine
Composition
Clonipres™ 0.1 Tablet: Each tablet contains Clonidine Hydrochloride USP 0.1 mg.
Indication
Clonidine is indicated in the treatment of hypertension. It may be employed alone or
concomitantly with other anti-hypertensive agents.
Other uses include:
i) Menopausal flushing
ii) Attention deficit hyperactivity disorder
iii) Opioid withdrawal & Alcohol withdrawal syndrome
iv) Tourette's syndrome
Dosage & Administration
Adult: The dose of Clonidine must be adjusted according to the patient's individual blood
pressure response.
Initial dose: 0.1 mg twice a day (morning & bed time). Elderly patients may be benefited
from a lower initial dose.
Maintenance dose: Further increments of 0.1 mg per day may be made at weekly
intervals if necessary, until the desired result is achieved. The therapeutic dose most
commonly employed have ranged from 0.2 mg to 0.6 mg per day given in divided doses.
In renal impairment, dose of Clonidine Hydrochloride must be adjusted according to the
degree of impairment & patient should be monitored carefully.
Menopausalflushing :0.1 mg to 0.4 mg daily
Attention deficit hyperactivity disorder :5 mcg/kg/day for 8 weeks
Alcohol withdrawal :0.3 to 0.6 mg every 6 hourly
Tourette's syndrome / 0.15 mg to 0.2 mg daily or as directed by the physician
Cefuroxime
Composition
Fixcef 250 Tablet: Each film coated tablet contains Cefuroxime Axetil BP equivalent to Cefuroxime 250 mg.
Indication
Pharyngitis/tonsillitis, Acute bacterial otitis media, Acute bacterial maxillary sinusitis.
Acute bacterial exacerbations of chronic bronchitis and secondary bacterial infection of acute bronchitis,
Uncomplicated skin and skin-structure infections, Uncomplicated urinary tract infections,
Uncomplicated gonorrhoea (urethral and endocervical), Early lyme disease (erythema migrans).
Dosage & Administration
Adolescents & adults(13 years & above)
Pharyngitis or Tonsillitis 250 mg twice daily for5 - 10 days
Acute bacterial maxillary sinusitis 250 mg twice daily for10 days
Acute bacterial exacerbation of chronic bronchitis 250 - 500 mg twice daily for 10 days
Secondary bacterial infections of acute bronchitis 250 - 500 mg twice daily for 5 - 10 days
Uncomplicated skin & skin-structure infections 250 - 500 mg twice daily for 10 days
Uncomplicated urinary tract infection 125 - 250 mg twice daily for 7 - 10 days
Uncomplicated gonorrhea 1000 mg single dose
Lyme disease 500 mg twice daily for 20 days
Paediatric patients (Upto12 years)
Acute otitis media 250 mg twice daily for 10 days
Acute bacterial maxillary sinusitis 250 mg twice daily for 10 days
Esomeprazole
Composition
Esotac20 Capsule: Each delayed release capsule contains Esomeprazole Magnesium Trihydrate USP equivalent to Esomeprazole 20 mg.
Esotac40 Capsule: Each delayed release capsule contains Esomeprazole Magnesium Trihydrate USP equivalent to Esomeprazole 40 mg.
Esotac20 Tablet: Each enteric coated tablet contains Esomeprazole Magnesium Trihydrate USP equivalent to Esomeprazole 20 mg.
Esotac40 Tablet: Each enteric coated tablet contains Esomeprazole Magnesium Trihydrate USP equivalent to Esomeprazole 40 mg.
Indication
1. Healing of erosive esophagitis
2. Long-term management of esophagitis
3. Symptomatic gastroesophageal reflux disease
4. H. pylori eradication for the treatment of duodenal ulcer (Triple therapy with Esomeprazole,
clarithromycin and amoxicillin)
Dose and Administration
Healing of erosive Esophagitis: 20 mg or 40 mg once daily for 4-8 weeks. For those patients who have not healed after 4-8 weeks of treatment, an additional 4-8 weeks course of Esomeprazole may be considered.Long-term management of esophagitis: 20 mg once daily. Symptomatic gastroesophageal reflux disease: 20 mg once daily for 4 weeks.
H. pylori eradication for the treatment of duodenal ulcer (Triple therapy): 20 mg Esomeprazole once daily with 500 mg clarithromycin twice daily and 1g amoxicillin twice daily for 7-10 days or as directed by the physician
Cefuroxime + Clavulanic Acid
Composition
Fixcef™ Plus 250 Tablet: Each film coated tablet contains Cefuroxime
Axetil BP equivalent to Cefuroxime 250 mg and Diluted Potassium
Clavulanate BP equivalent to Clavulanic Acid 62.5 mg.
Fixcef™ Plus 500 Tablet: Each film coated tablet contains Cefuroxime Axetil BP equivalent to Cefuroxime 500 mg and Diluted Potassium Clavulanate BP equivalent to Clavulanic Acid 125 mg.
Indication
Pharyngitis/tonsillitis, Acute bacterial otitis media, Acute bacterial maxillary sinusitis.
Acute bacterial exacerbations of chronic bronchitis and secondary bacterial infection of acute bronchitis, Uncomplicated skin and skin-structure infections, Uncomplicated urinary tract infections, Uncomplicated gonorrhoea (urethral and endocervical), Early
lyme disease (erythema migrans).
Dosage & Administration
For oral administration
Fixcef™ Plus Tablet: The usual course of therapy with Cefuroxime-Clavulanic acid tablets is 5 to 7 days for treatment of bronchitis and 7 to 10 days for other infections. Adolescents andAdults (13 years and older)
Polyethylene Glycol + Propylene Glycol
Composition
Syscol™ Sterile Eye Drops: Each ml contains
Polyethylene Glycol 400 USP 4 mg & Propylene
Glycol BP 3 mg.
Preservative: Sodium Perborate BP 0.001%
Indications
Syscol™ Sterile Eye Drops is indicated for the
temporary relief of burning and irritation due to
dryness of the eye.
Dosage and administration
Instill 1 drop 4 times daily in the affected eye(s) or as
needed or as directed by the physician.
Bilastine
Composition
Allertin 20 Tablet: Each tablet contains Bilastine INN 20 mg.
Allertin ODT 10: Each orally disintegrating tablet contains Bilastine INN 10 mg.
Allertin Oral Solution: Each ml oral solution contains Bilastine INN 2.5 mg.
Indication
Seasonal Allergic Rhinitis: Bilastine is indicated for the symptomatic relief of nasal and non-nasal symptoms of seasonal allergic rhinitis (SAR) in patients of 4 years and older.
Chronic Spontaneous Urticaria: Bilastine is indicated for the relief of the symptoms associated with chronic spontaneous urticaria (CSU) (e.g. pruritus and hives), in patients of 4 years of age and older.
Dosage & Administration
Allertin 20 Tablet: Adults and adolescents 12 years of age and above: 20 mg tablet once daily. The tablet should be taken one hour before or two hours after intake of food.
Allertin Oral Solution: 4 ml of oral solution once daily for children 4 to 11 years of age. Recently, it has been approved in Latin America for children from 2 years of age. The oral solution should be taken one hour before or two hours after intake of food or fruit juice. Allertin ODT 10: The maximum recommended daily dose for children in
between 4 to 11 years is 10 mg Bilastine orally disintegrating tablet (1 tablet) and should not be exceed. If a dose is missed, the next scheduled dose should be taken. An extra dose is not necessary or as directed by the physician.
Ambroxol
Composition:
BroxTM syrup: Each 5 ml syrup contains Ambroxol Hydrochloride BP 15 mg.
BroxTM paediatric drops: Each ml contains Ambroxol Hydrochloride BP 6 mg.
Indication:
Productive cough
Acute and chronic diseases of respiratory tracts associated with
viscid mucus including acute and chronic bronchitis.
Inflammatory diseases of rhinopharyngeal tract (e.g. laryngitis,pharyngitis, sinusitis and rhinitis) associated with viscid mucus.
Asthmatic bronchitis, bronchial asthma with difficult departure of mucus
Bronchiectasis
Chronic pneumonia
Dose & Administration:
Average daily dose (preferably after meal):
Brox Paediatric Drops
0-6 months: 0.5 ml 2 times a day
6-12 months: 1 ml 2 times a day
1-2 years: 1.25 ml 2 times a day
Brox Syrup
2-5 years old: 2.5 ml (1/2 teaspoonful) 2-3 times a day
5-10 years old: 5 ml (1 teaspoonful) 2-3 times a day
Above 10 years old: 10 ml (2 teaspoonful) 3 times a day
Or as directed by the physician
Alogliptin
Composition
Aloglip 6.25 Tablet: Each film coated tablet contains Alogliptin Benzoate INN equivalent to Alogliptin 6.25 mg.
Aloglip 12.5 Tablet: Each film coated tablet contains Alogliptin Benzoate INN equivalent to Alogliptin 12.5 mg.
Aloglip 25 Tablet: Each film coated tablet contains Alogliptin Benzoate INN equivalent to Alogliptin 25 mg.
Indication
Aloglip is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type-2 diabetes mellitus.
Dose & Administration
The recommended dose in patients with normal renal function or mild renal impairment is 25 mg once daily or as directed by the physicians.
Cetrizine
Composition:
Trizin™ Sterile Eye Drops: Each ml contains Cetirizine
Dihydrochloride BP equivalent to Cetirizine 2.40 mg.
Preservative: Sodium Perborate BP 0.001%.
Indications:
Trizin™ Sterile Eye Drop is indicated for the treatment of
ocular itching associated with allergic conjunctivitis.
Dosage and administration:
The recommended dosage of Trizin™ Sterile Eye Drop is
to instill one drop in each affected eye twice daily
(approximately 8 hours apart) or directed by the
physician.
Nepafenac
Composition:
Neparact™ TS Sterile Eye Suspension: Each ml contains Nepafenac INN 3 mg.
Preservative: Sodium Perborate BP 0.001%
Indications:
Neparact™ TS Sterile Eye Suspension is indicated for-
The treatment of post-operative ocular pain and
inflammation including cataract surgery.
Dosage & administration:
•Instill 1 drop once daily 1 day prior to cataract surgery
and continued on the day of surgery and through the
first 2 weeks of the post-operative period.
•An additional drop should be administered 30 to 120
minutes prior to surgery.
Levofloxacin
Composition:
Levoquin TS
Sterile Eye Drops: Each ml contains Levofloxacin Hemihydrate USP equivalent
Levofloxacin 15 mg.
Indications:
Levoquin TS Sterile Eye Drops is indicated for the
treatment of bacterial conjunctivitis caused by susceptible strains of
gram-positive bacteria.
Dosage & Administration:
Levoquin TS Sterile Eye Drops:
Days 1 & 3: Instill 1 drop in the affected eye(s) every 30 minutes to 2 hours while awake per day.
Days 4 to completion: Instill 1 drop in the affected eye(s) every 1-4 hours while awake per day.
or as directed by the physician
Hypromellose
Composition
Iclear™ Sterile Eye Drops: Each ml contains
Hypromellose BP 3 mg.
Indications
Hypromellose is used to treat dry eye conditions
where reduced or absent of normal lachrymal
secretion. Lachrymal secretions (tears) are
produced to keep the eye lubricated and clean.
Dosage and Administration
Therapy of dry eye syndrome requires an individual
dosage regimen.The usual dose for Iclear is 1 drop
into the conjunctival sac 3 to 5 times per day or as
directed by the physician or as directed by the
physician.
Moxifloxacin
Composition
Cinagen™ Sterile Eye Drops: Each ml contains Moxifloxacin Hydrochloride BP equivalent to Moxifloxacin 5 mg.
Indications
Cinagen™ is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of following organisms:
Aerobic gram-positive microorganism: Corynebacterium species, Micrococus luteus, Staphylococcus aureus, Staphylococus epidermis, Staphylococus haemolyticus, Staphylococcus hominis, Staphylococcus warneri, Streptococcus pneumoniae, Streptococcus viridans group Aerobic Gram-negative microorganisms: Acinetobacter iwoffi, Haemophilusinfluenzae, Haemophilus parainfluenzae.
Dosage and administration
Cinagen™ Sterile Eye Drops: One drop in the affected eyes 3 times per day for 7 days or as directed by the physician.
Carboxymethylcellulose
Presentation
Cfresh™ Liquigel: Each ml Sterile lubricant eye drops
contain Carboxymethylcellulose Sodium USP 10 mg.
Preservative: Sodium Perborate 0.001%
Indications
It is indicated for use as a lubricant in dry eye
(keratoconjunctivitis sicca) including relief of burning,
irritation and/or discomfort due to dryness of the eye.
Dosage and Application
Instill 1 or 2 drops in the affected eye(s) or as directed by the physician.
Glycerin + Hypromellose + Polyethylene glycol + Tetrahydrozoline + Zinc Sulfate
Composition:
Artiforte™ Sterile Eye Drops: Each ml contains Glycerin
USP 2 mg, Hypromellose BP 3.6 mg, Polyethylene glycol
400 USP 10 mg, Tetrahydrozoline Hydrochloride USP 0.5
mg, Zinc Sulfate Monohydrate USP equivalent to Zinc
Sulfate 2.5 mg. Preservative: Sodium Perborate BP 0.001%.
Indications:
Artiforte™ is indicated for the relief of discomfort and
redness of the eye due to minor eye irritations, for relief of
dryness of the eye, for the temporary relief of burning and
irritation due to exposure to wind or sun, for protection
against further irritation.
Dosage and Administration:
1 to 2 drops in the affected eye(s) up to 4 times daily or as
directed by the physician.
Children under 6 years of age: as per suggestion of
physician or as directed by the physician
Montelukast
Composition:
ArokastTM4 FT: Each flash tablet contains Montelukast Sodium USP equivalent to
Montelukast 4 mg.
ArokastTM5 FT: Each flash tablet contains Montelukast Sodium USP equivalent to
Montelukast 5 mg.
ArokastTM10: Each film coated tablet contains Montelukast Sodium USP equivalent to
Montelukast 10 mg.
Pharmacology:
Montelukast is orally active and selective leukotriene receptor antagonist that inhibits the
cysteinyl leukotriene CysLT1 receptor. Cysteinyl leukotrienes and leukotriene receptor
occupation have been correlated with the pathophysiology of asthma (such as, airway
oedema, smooth muscle contraction and altered cellular activity associated with the
inflammatory process, which contribute to the signs and symptoms of asthma).
Indication:
Montelukast is indicated for the prophylaxis of asthma and management of chronic
asthma; symptomatic relief of seasonal allergic rhinitis in patients with asthma.
Dosage & Administration:
Prophylaxis of asthma:
Adult and Child over 15 years: 10 mg once daily in the evening.
Child 6-15 years: 5 mg once daily in the evening.
Child 6 months-6 years: 4 mg once daily in the evening.
Seasonal allergic rhinitis:
Adult and Child over 15 years, 10 mg once daily in the evening.
The safety and efficacy of Montelukast was demonstrated in clinical trials where it was
administered in the evening without regard to the time of food ingestion.
Desloratadine
COMPOSITION :
Desatrol™Tablet : Each film coated tablet contains Desloratadine BP 5 mg.
Desatrol™Syrup : Each 5 ml syrup contains Desloratadine BP 2.5 mg.
INDICATION :
Allergic Rhinitis: Desatrol™ is indicated for the relief of the nasal and nonnasal symptoms of allergic rhinitis (seasonal and perennial).
Chronic idiopathic Urticaria: Desatrol™ is indicated for the symptomatic relief of pruritus, reduction in the number of hives and size of hives, in patients with chronic idiopathic urticaria.
DOSE AND ADMINISTRATION :
Tablet : In adults and children 12 years of age and over, the recommended dose is 5 mg once daily.
In patients with liver or renal impairment, a starting dose of one 5 mg tablet every other day is recommended.
Syrup : Children 2-5 years of age : 2.5 ml once daily, 6-11 years of age : 5 ml once daily. Adults and children 12 years of age and over : 10 ml once daily. It may be administered with or without food. Or as directed by the physician.
Fexofenadine
Composition:
Odafen™ 120: Each film coated tablet contains Fexofenadine
Hydrochloride USP 120 mg.
Odafen™ 180: Each film coated tablet contains Fexofenadine
Hydrochloride USP 180 mg.
Odafen™ Suspension: Each 5 ml suspension contains Fexofenadine Hydrochloride USP 30 mg.
Indication:
Seasonal Allergic Rhinitis:
Odafen™ tablet are indicated for the relief of symptoms
associated with seasonal allergic rhinitis in adults and children 6 years of age and older. Odafen™ oral suspension is indicated for the relief of symptoms associated with seasonal allergic rhinitis in children 2 to 11 years of age. Symptoms to treat
effectively:
sneezing, rhinorrhea, itchy nose/palate/throat, itchy/watery/red eyes.
Chronic Idiopathic Urticaria:
Odafen™ of Chronic Idiopathic Urticaria in adults and children 6 years of age and
older.
Odafen™ manifestations of Chronic Idiopathic Urticaria in children 6 months to 11 years
of age. Fexofenadine Hydrochloride significantly reduces pruritus and the number
of wheals.
Ketotifen
Composition
Toma™ Tablet: Each tablet contains Ketotifen Fumarate BP equivalent to 1 mg Ketotifen.
Toma™ Syrup: Each 5 ml syrup contains Ketotifen Fumarate BP equivalent to 1mg Ketotifen
Indication
• Prophylactic treatment of bronchial asthma.
• Allergic rhinitis ( seasonal and perennial).
• Allergic conjunctivitis.
• Allergic conditions such as hay fever, itchy rash.
Dose & Administration
Adult: 1 mg twice daily with food. If necessary the dose may be increased to 2mg twice daily in severe cases.
Children above 2 years: 1 mg twice daily with food.
From 6 month to 2 years: 0.05 mg (0.25 ml) per kg of body weight twice daily.
Use in elderly: Same as adult dose.
Missed dose: If a dose is missed, should be taken as soon as possible. If it is almost time for the next dose, skip the missed dose and the regular dosing schedule should be maintained. Dose should not be doubled in case of a missed dose.
Patient's known to be easily sedated should begin treatment with 0.5 to 1 mg at night for the first few days or as directed by the physician
Hyoscine Hydrobromide
Composition:
Joytrip™150: Each chewable tablet contains Hyoscine
Hydrobromide BP 150 meg.
Joytrip™300: Each tablet contains Hyoscine Hydrobromide BP
300 meg.
Indication:
Prevention and control of nausea and vomiting associated with motion sickness/travel sickness.
Dosage & Administration:
Ideally, take tablets 30 minutes before journey. Adults and
children over 13 years: 300 meg (Maximum 900 meg in 24
hours). Children age 7-12 years: 150-300 meg (Maximum 300
meg in 24 hours). Children age 4-7 years: 150 meg (Maximum
300 meg in 24 hours). Children age 3-4 years: 75 meg
(Maximum 150 meg in 24 hours). Not recommended under 3
years or as directed by the physician.
Dexlansoprazole
Composition
Dextac™30 Capsule:Each capsule contains Dexlansoprazole INN 30 mg as enteric coated pellets.
Dextac™60 Capsule:Each capsule contains Dexlansoprazole INN 60 mg as enteric coated pellets.
Indication
• Healing of Erosive Esophagitis: Dextac™ (Dexlansoprazole) is indicated for healing of all grades of Erosive Esophagitis (EE) for up to 8 weeks.
• Maintenance of Healed Erosive Esophagitis: Dextac™ (Dexlansoprazole) is indicated to maintain healing of EE and relief of heartburn for up to 6 months.
• Symptomatic Non-Erosive Gastroesophageal Reflux Disease: Dextac™ (Dexlansoprazole) is indicated for the treatment of heartburn associated with symptomatic Non-Erosive Gastroesophageal Reflux Disease (GERD) for upto 4 weeks.
Dose & Administration
Important Administration Information
• Dextac™ (Dexlansoprazole) can be taken without regard to food or the timing of food.
• Dextac™ (Dexlansoprazole) should be swallowed whole.
Alternatively, Dextac™ (Dexlansoprazole) capsules can be administered as follows:
- Open capsule.
- Sprinkle intact granules on one table spoon.
- Swallow immediately. Granules should not be chewed.
Missed Dose: If a capsule is missed at its usual time, it should be taken as soon as possible. But
if it is too close to the time of the next dose, only the prescribed dose should be taken at the
appointed time. A double dose should not be taken. or as directed by the physicians.
Pizotifen
COMPOSITION :
Pizofen™ Tablet : Each film coated tablet contains Pizotifen
malate BP equivalent to Pizotifen 0.5 mg
Pizofen™ TS Tablet : Each film coated tablet contains Pizotifen
malate BP equivalent to Pizotifen 1.5 mg
INDICATION :
It is used as prophylactic treatment of vascular headaches of the migraine types, such as classic migraine, common migraine and cluster headache.
DOSE AND ADMINISTRATION :
Adult : Usually 1.5 mg daily, which may be taken as a single
dose at night or in three divided doses. Dose should be adjusted to individual patient's requirements. Upto a maximum of 4.5 mg may be given as a single dose daily.
Children : Dose is 1 mg as a single dose at night using 0.5 mg
tablet. Maximum dose is upto 1.5 mg daily usually in divided
dose.
Or as directed by the physician.
Naftifine
Composition:
Nafgal Cream: Each gram cream contains Naftifine Hydrochloride USP 20 mg.
Indications:
Nafgal Cream is indicated for the treatment of interdigital tinea pedis, tinea cruris and tinea corporis caused by the organism Trichophyton rubrum.
Dosage & Administration:
Apply a thin layer of Nafgal Cream once-daily to the affected areas plus half inch margin of healthy surrounding skin for 2 weeks or as directed by the physician.
Cefixime
Composition:
Duracef™ 200 Capsule: Each capsule contains Cefixime Trihydrate BP equivalent to Cefixime 200 mg.
Duracef™ 400 Capsule: Each capsule contains Cefixime Trihydrate BP equivalent to Cefixime 400 mg.
Duracef™ DS PFS (50 ml): Each 5 ml reconstituted suspension contains Cefixime Trihydrate BP equivalent to Cefixime 200 mg.
Duracef™ PFS (50 ml): Each 5 ml reconstituted suspension contains Cefixime Trihydrate BP equivalent to Cefixime 100 mg.
Duracef™ PFS (30 ml): Each 5 ml reconstituted suspension contains Cefixime Trihydrate BP equivalent to Cefixime 100 mg.
Duracef™ Paediatric Drops (21 ml): Each ml reconstituted suspension contains Cefixime Trihydrate BP equivalent to Cefixime 25 mg.
Duracef™ Max PFS (10 ml): Each 5 ml reconstituted suspension contains Cefixime Trihydrate BP equivalent to Cefixime 500 mg.
Duracef™ Max PFS (20 ml): Each 5 ml reconstituted suspension contains Cefixime Trihydrate BP equivalent to Cefixime 500 mg.
Indications:
Otitis media- caused by Streptococcus pneumoniae (including Penicillinase resistant strains), Streptococcus pyogenes, Haemophilus influenzae (including beta-lactamase producing strains), Moraxella catarrhalis (including beta-lactamase producing strains). Pharyngitis/Tonsillitis- caused by Streptococcus pyogenes. Uncomplicated Urinary Tract infection- Caused by E. coli, Proteus mirabilis. Uncomplicated Gonorrhoea- Caused by N. gonorrhoeae (including Penicillinase & nonPenicillinase resistant strains).
Dosage and Administration:
Adults: The recommended dose is given as a single dose of 400 mg or 200 mg twice daily for 7-14 days according to the severity of infections. Uncomplicated Gonorrhoea. 400 mg single dose.
Children:
> 6 months: 8 mg /kg/ day in 1-2 divided doses
6 months-1 year: 75 mg daily
1-4 years: 100 mg daily
5-10 years: 200 mg daily
> 10 years: As same as adult dose or as directed by the physician
Olopatadine
Composition:
Alleloc™ DS Sterile Eye Drops: Each ml contains Olopatadine
Hydrochloride USP equivalent to Olopatadine 2 mg.
Indications:
Allergic conjunctivitis.
Dosage and administration:
Alleloc™ DS: Instill one drop in the affected eye (s) once daily
or as directed by the physician.
